<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="571">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04544891</url>
  </required_header>
  <id_info>
    <org_study_id>2020PI120</org_study_id>
    <nct_id>NCT04544891</nct_id>
  </id_info>
  <brief_title>TREM-1 Pathway Activation in COVID-19</brief_title>
  <acronym>CoviTrem1</acronym>
  <official_title>Prognostic Significance of the TREM-1 Pathway Activation in COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inotrem</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe Acute Respiratory Syndrome-Corona Virus-2 infection results in a mild infection in
      most of the patients. However, 15-20% require hospitalization, and among them, 15-20% will
      develop acute respiratory failure, leading to their admission in Intensive Care Unit. There
      are no accepted predictive criteria for aggravation. Severe forms of Coronavirus induced
      disease-19 (COVID-19) are the consequence of endotheliopathy, and hyperinflammatory and
      pro-coagulant state. The Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) is an
      immunoreceptor that acts as an amplifier of the inflammatory response. TREM-1 is expressed on
      myeloid and endothelial cells. Its activation leads to endothelial activation and damage,
      hyperinflammatory, and pro-coagulant state. TREM-1 activation is associated with poor outcome
      during septic shock and myocardial infarction.

      We here aim at investigating the relationship between TREM-1 pathway activation and clinical
      degradation and outcome of COVID-19 hospitalized patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>prognostic value of the TREM-1 pathway activation on clinical worsening</measure>
    <time_frame>day 28</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Covid19</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <description>Blood will be collected every 3 days until Day 28, discharge, or death</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1000 consecutive COVID-19 patients hospitalized for less than 3 days; among them at least
        200 patients hospitalized in ICU (primary admission or secondary transfer from the ward)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria Consecutive COVID-19 hospitalized patients for less than 3 days

        Exclusion Criteria:

        No consent Pregnancy protected populations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>CHRU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Bruno Francois, MD</last_name>
      <email>bruno.francois@chu-limoges.fr</email>
    </contact>
    <contact_backup>
      <last_name>Bruno Francois</last_name>
      <email>bruno.francois@chu-limoges.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Central hospital</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2020</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Gibot SÃ©bastien</investigator_full_name>
    <investigator_title>Pr</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

